Diseases of the Nervous System, Phase II-III

RISE 2

Volunteers
Health Professionals

What is the purpose of this trial?

This research study is being done to see the effectiveness and safety of a new drug called BHV-7000 as a possible treatment for focal seizures for patients who are taking antiseizure medications (ASMs) and still experience seizures. Refractory focal epilepsy is when someone continues to have focal seizures despite treatment with ASMs or other treatments.

Ages
18 years - 75 years
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Divya Bhaskar, Study Coordinator

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Aline Herlopian, MD
Associate Professor Term; Affiliated Faculty , Yale Institute for Global Health; Medical Director, Clinical Neurophysiology/EEG lab, Neurology; Director, Clinical trials in Epilepsy , Neurology

Sub-Investigators

Last Updated
10/21/2025
Study IRB
#2000037579